Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed and dated informed consent form prior to any study specific procedures.~2. Males or females aged 18 to 80 years, inclusive, at Screening (Visit 1).~3. Females must be non-pregnant and non-lactating.~4. Patients on phosphate binder therapy must be on chronic maintenance hemodialysis (HD) 3 times per week for at least 3 months or chronic maintenance peritoneal dialysis (PD) for a minimum of 6 months. If modality of dialysis has changed, the patient must meet one of the two dialysis criteria above and been on the new modality of dialysis for a minimum of one month. Phosphate binder naïve patients must be on chronic maintenance HD 3 times per week or chronic maintenance PD.~5. Kt/V ≥1.2 at most recent measurement prior to Screening (Visit 1).~6. Prescribed and taking phosphate binder medication at least 3 times per day or being phosphate binder naïve; defined as having not taken phosphate binders for at least 3 months prior to Screening. The patient must be taking a minimum of 6 pills per day for Renvela, Auryxia, or PhosLo; and/or a minimum of 3 pills per day for Fosrenol or Velphoro.~7. For patients taking phosphate binders, both the s-P level at the most recent measurement prior to Screening (Visit 1) and the s-P level at Screening (Visit 1) must be \>5.5 and ≤10.0 mg/dL.~8. For phosphate binder naïve patients, the s-P level at Screening (Visit 1) must be \>4.5 and ≤10.0 mg/dL.~9. Able to understand and comply with the protocol.~Exclusion Criteria:~1. Severe hyperphosphatemia defined as having an s-P level \>10.0 mg/dL at any time point during routine clinical monitoring for the 3 preceding months before Screening (Visit 1).~2. Serum/plasma PTH \>1200 pg/mL. The most recent value from the patient's medical records should be used.~3. Clinical signs of hypovolemia at Screening (Visit 1) as judged by the Investigator.~4. History of inflammatory bowel disease or irritable bowel syndrome with diarrhea.~5. Scheduled for living donor kidney transplant or plans to relocate to another center during the study.~6. Use of an investigational agent within 30 days prior to Screening (Visit 1).~7. Involvement in the planning and/or conduct of the study (applies to both Ardelyx/Contract Research Organization (CRO) staff and/or staff at the study site).~8. If, in the opinion of the Investigator, the patient is unable or unwilling to fulfill the requirements of the protocol or has a condition which would render the results uninterpretable.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1: Straight Switch (Type: EXPERIMENTAL): Patients stop taking phosphate binders and start tenapanor 30 mg twice daily
- Cohort 2: Decrease Phosphate Binder by 50% (Type: EXPERIMENTAL): Decreases phosphate binder dose by at least 50% with the ability to switch the binder regiment from thrice daily (TID) to BID or once a day and initiates tenapanor 30 mg BID
- Cohort 3: Phosphate Binder Naive (Type: EXPERIMENTAL): Phosphate binder naive patients are enrolled as Cohort 3 and receive tenapanor with a starting dose of 30 mg/BID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete